




RealRate

PHARMACEUTICAL 2018

Dicerna Pharmaceuticals Inc
Rank 96 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 321%, being 70% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	118,558
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,646
Liabilities, Non-Current	0
Other Assets	814
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,000
Other Net Income	539
Other Revenues	2,277
Property and Equipment	1,512
Research and Development	36,983
Selling, General and Administrative Expense	25,881

Output Variable	Value in 1000 USD
Assets	120,884
Liabilities	19,646
Expenses	62,864
Revenues	2,277
Stockholders Equity	101,238
Net Income	-60,048
Comprehensive Net Income	-60,048
BaseVar	103,105
ECR before Limited Liability	229%
Economic Capital Ratio	321%